246 Users Online
Immunoassay Interference Blocker Market Segmented Antibody Interference Blockers, Detection Interference Blockers, Surface Interference Blockers Product in Sandwich Immunoassays, Antibody Capture Assays, Competitive ELISA Application
Worldwide revenue from the immunoassay interference blocker market was about US$ 253.1 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 6.1% to reach a valuation of US$ 489.6 Mn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Immunoassay Interference Blocker Market Size (2022) |
US$ 253.1 Mn |
|
Projected Market Value (2033) |
US$ 489.6 Mn |
|
Global Market Growth Rate (2023-2033) |
6.1% CAGR |
|
Market Share of Top 5 Countries |
53.3% |
As assessed by Persistence Market Research, antibody interference blockers segment is expected to hold a largest market value of US$ 146.0 Mn by 2023. Overall, immunoassay interference blocker market sales account for approximately 12.6% revenue share in the global enzyme linked immunosorbent assay (ELISA) market, which was valued at around US$ 2.0 Bn at the end of 2022.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global market for immunoassay interference blocker recorded a historic CAGR of 6.0% in the last 8 years from 2014 to 2022.
The demand for immunoassay interference blocker kits and reagents is expected to increase due to the rapidly expanding frequency of chronic diseases and the ageing of the global population, as well as the rising use of biochemical testing. The market for immunoassay interference blockers has a lot of potential in the near future because of their widespread use in diagnostic and other immunoassay tests as a result of cooperative R&D between manufacturers and researchers to create and market newer and more effective immunoassay interference blockers.
Additionally, to acknowledge the superior performance quality of immunoassays, academic institutions, research organizations, and biotechnology enterprises have grown into a prominent consumer base, branded by untapped product niches for immunoassay interference blockers. Manufacturers of immunoassay interference blockers have been able to take advantage of this new, dormant opportunity as a result.
Immunoassay interference blocker manufacturers are working together to develop advanced instruments, kits, and materials that can quickly identify a variety of chronic diseases. This is anticipated to define the intensity of the progression of cancer and other infectious and viral disorders, as well as the anticipated patient survival time. This offers an industry growth opportunity while maintaining the ongoing research in molecular diagnostics.
The global market is thus likely to show high growth over the coming years at a CAGR of 6.1% and reach a global market size of US$ 489.6 Mn by 2033.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version“Economic Boom in Asia Pacific Countries Offer Great Revenue Opportunity”
In APAC, demand for healthcare has been rising rapidly. For market players, the region offers tremendous growth prospects. The health sector has benefited from the continuous economic expansion in countries like India, China, Japan, and Indonesia. Governments in these nations are working harder to improve healthcare services, facilities, and supplies. The region's healthcare sector is expanding as a result of rising per capita income and health expenditures.
“Well Structured Regulatory Framework in Developed Countries”
The development of a well-organized regulatory framework for biochemical testing, particularly in North America and Europe, has had a significant impact on the outlook for the global immunoassay interference blocker market.
“Rising prevalence of Risk Factors”
Over the past few years, there have been more businesses competing in the immunoassay interference blocker market. Based on well-established NAT technologies and immunoassays, the market for interference blockers for immunoassays has grown. Although Roche, Thermo Fisher Scientific, and Bio-Rad Laboratories, Inc. continue to control the NAT industry, numerous other biotechnology companies have lately acquired considerable IP property in this field.
“Low FDA Approvals”
The FDA's approval of immunoassay interference blocker kits and reagents has had a significant negative impact on the growth of the market globally. Due to the lack of clinical evidence supporting the use of molecular diagnostic tools, such as immunoassay interference blocker kits, possible issues have arisen due to the FDA's slow approval process. The less generous reimbursement policies are another hindrance to the market. One of the main issues impeding the growth of the entire industry is a lack of transparency and knowledge about the diagnostic processes used to identify various diseases and chronic disorders.
“Unfavourable Reimbursement Policies”
The unfavourable reimbursement environment in numerous areas is impeding the development of novel technologies like human serum-derived antibody interference blockers, which is limiting the market for immunoassay interference blockers. Immunoassay interference blocker reagent and kit reimbursement is a crucial issue for payers as well as providers of diagnostic reagents since, although though diagnostics only account for 5 to 7% of hospital costs, they are used in about 70% of clinical decisions. Molecular diagnostic tests and other emerging technologies, such as Sandwich Immunoassay, Antibody Capture Assays, Competitive ELISA, and others, may encounter additional challenges in obtaining reimbursement clearance, which could hinder their adoption by healthcare providers.
Sales Team
Client Partner
Why is the U.S. Market Booming?
“Vast Presence of Biotechnology Companies”
The U.S. is expected to hold around 30.6% market share in the global immunoassay interference blocker market at the end of 2023.
Increased molecular diagnostics, increased demand for inexpensive healthcare and cost-effective medications, a developed and expanding healthcare system, and the presence of significant immunoassay interference blocker suppliers in the nation all contribute to the market's growth.
Will the Germany Be a Lucrative Market for the Manufacturers?
“Aging Population and Prevalence of Chronic Diseases”
With a 4.5% market share, Germany will hold a fair amount of share in global market at the end of 2023.
The need for biochemical testing for the management of chronic diseases is anticipated to increase due to reasons such as the rising prevalence of chronic diseases and the ageing population across the country. The demand for diagnostic kits and reagents for the detection of age-related and other chronic illnesses is projected to increase as the population ages.
How is Japan Emerging as a Prominent Market for Immunoassay Interference Blocker?
“Vast Patient Pool Suffering from Eye Disorders”
Japan is estimated to hold market share of about 8.5% of the global immunoassay interference blocker market in 2023.
Rapid use of molecular diagnostic methods to diagnose cancer and to fuel the expansion of the immunoassay interference market.
Which Product is Driving Growth of the Global Market?
“Better Accuracy in assay”
Antibody interference blockers segment is expected to hold highest market value of US$ 146.0 Mn by 2023 within the total drug class segment by the end of 2023.
Antibody interference blockers have become incredibly popular and could experience significant growth throughout the anticipated future. In order to ensure the accuracy of the assay, these are utilized to reduce non-specific interaction and other interferences, specifically from rheumatoid factor, anti-mouse antibodies, and heterophilic antibodies that can result in false-positive results in both competitive and paired monoclonal sandwich assays. This will accelerate the segment's growth in the ensuing years.
Which Application is Expected to Dominate the Global Market?
“Growing and Research Development Activities”
Antibody capture assays segment is expected to be the dominating segment by the end of 2023 with majority of the market of about 39.8%.
The growing research and development activities in various health applications such as oncology and academic & research institution research & experimental studies/experiments have let to the dominance of antibody capture assays.
Which End User is Expected to Emerge as a Market Leader in the Future?
“Increasing Number of Hospitals with Better Infrastructure”
Academic and Research Institutes is expected to hold the larger share of about 39.7% by the end of 2023.
Due to their expanding research efforts, Academic and Research Institutes will continue to lead the segments during the projection period. Additionally, the expansion of research and development activities in numerous health applications to provide better and enhanced diagnostic products with the highest degree of precision will also contribute to industry growth.
Manufacturers are concentrating on diversifying their product lines by introducing new, advanced products and securing approval from various governmental agencies. Leading providers of immunoassay blockers are actively engaged in strategic product development and expansion through partnerships in order to increase their market position.
Key instances include:
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2014-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Key Companies’ Profile |
|
|
Customization & Pricing |
Available upon Request |
Product:
Application:
End User:
Region:
The global market is currently valued at around US$ 253.1 Mn in 2022.
Sales of the market are set to witness growth at a CAGR of 6.1% and be valued at around US$ 489.6 Mn by 2033.
Demand for the market increased at a 6.0% CAGR from 2014 to 2022.
U.S., China, Germany, India, and Japan accounted for the major share in the global market as of year 2022, holding around 53.3% market share.
The U.S. is expected to hold around 30.6% market share in the global immunoassay interference blocker market at the end of 2023.
Latin America will account for around 10.8% share of the global market in 2023.
Japan is estimated to hold market share of about 8.5% of the global immunoassay interference blocker market in 2023.
Germany held about 4.5% of the global market share at the end of 2023.
China is set to expand at a CAGR rate of 6.6% over the forecast period.
India is set to expand at a CAGR rate of 6.9% over the forecast period.
